VeriMomБезопасен ли dihydroquercetin при беременности?
No harmonised CLP reproductive classifications (no H360/H361) and no CIR or SCCS safety assessment indicating reproductive hazard. Peer‑reviewed literature on taxifolin (dihydroquercetin) reports antioxidant and pharmacologic effects but does not provide evidence of teratogenicity or reproductive toxicity in humans; ECHA entries are registrations/self‑notifications without harmonised reproductive classification. Dermal exposure from cosmetics is expected to be low but measurable based on compound physicochemistry and cosmetic use patterns (PubChem; ECHA registration dossiers; PubMed).
Pregnancy-safe products containing dihydroquercetin
Related ingredients
Frequently asked questions
- Безопасен ли dihydroquercetin при беременности?
- No harmonised CLP reproductive classifications (no H360/H361) and no CIR or SCCS safety assessment indicating reproductive hazard. Peer‑reviewed literature on taxifolin (dihydroquercetin) reports antioxidant and pharmacologic effects but does not provide evidence of teratogenicity or reproductive toxicity in humans; ECHA entries are registrations/self‑notifications without harmonised reproductive classification. Dermal exposure from cosmetics is expected to be low but measurable based on compound physicochemistry and cosmetic use patterns (PubChem; ECHA registration dossiers; PubMed).
- Безопасен ли dihydroquercetin при грудном вскармливании?
- No evidence of reproductive or lactation toxicity or of mechanisms that would specifically target lactation transfer. No harmonised classifications or regulatory warnings for breastfeeding. Systemic exposure from topical use is expected to be low but measurable; transfer into breast milk is not documented in the literature.
- Безопасен ли dihydroquercetin для кожи малыша?
- No infant‑specific reproductive or developmental toxicity data identified. Hazard and mechanistic evidence for developmental effects are absent. Exposure score increased for baby skin because infant/young child skin has higher surface‑area‑to‑weight and a less mature barrier, so low/measurable adult dermal absorption is plausibly higher in infants (PubChem; ECHA registration dossiers; PubMed).
- Как VeriMom оценивает dihydroquercetin?
- VeriMom оценивает dihydroquercetin в 93/100 (без известных рисков) на основе EU CosIng, классификаций ECHA и исследований PubMed.
- Какие безопасные альтернативы dihydroquercetin при беременности?
- См. наш список безопасных альтернатив dihydroquercetin с аналогичной функцией и классификацией без известных рисков.
Проверь любой состав за 2 секунды
Скачай VeriMom бесплатно — отсканируй любой продукт и мгновенно получи оценку безопасности при беременности.
Медицинская оговорка
Данная информация предоставлена исключительно в образовательных целях и не является медицинской рекомендацией. Оценки безопасности основаны на общедоступных данных и могут не отражать все риски. Всегда консультируйтесь с вашим врачом перед использованием любых средств во время беременности или грудного вскармливания.